Non-Alkolik Yağlı Karaciğer Hastalığında İnflamatuvar Proteinler

Non-Alkolik Yağlı Karaciğer Hastalığı (NAYKH) yüksek miktarda alkol tüketimi hikâyesi ya da ikincil bir nedene bağlı hepatik steatozu olmayan kişilerde karaciğerde fazla yağ birikimi durumudur. NAYKH Kronik karaciğer hastalıklarının en önemli nedenlerinden biri olan NAYKH obezite ve insülin direnciyle yakından ilişkilidir. Son yıllarda yapılan çalışmalar, obezite ve obeziteyle ilişkili durumlar olan NAYKH, tip 2 diyabet ve metabolik sendrom ile kronik inflamasyon arasında bağlantı olabileceğini ileri sürmektedir. Klinik çalışmalar dünya genelinde hastalığın prevalansının arttığını göstermektedir. Hastalığın son yıllardaki görülme sıklığının artışı hastalığın oluşum mekanizmaları ve nedenlerine olan ilgiyi artırmıştır. Özellikle son yıllarda yapılan çalışmalar adipoz dokunun enerji depolama dışında, salgıladığı adipokinler ya da adipositokinler ile NAYKH'ın başlangıcını tetikleyen kaynaklardan biri olduğunu göstermektedir. Bu derlemenin amacı leptin, tümör nekroz faktörü (TNF)-?, interlökin (IL)-6, retinol bağlayıcı protein (RBP)-4, adiponektin, resistin, visfatin, apelin, kimerin gibi adipokinlerin NAYKH patojenezindeki etkilerini incelemektir

Inflammatory Markers in Non-Alcoholic Fatty Liver Disease

Non- Alcoholic Fatty Liver Disease (NAFLD) is a situation in which extra lipid accumulates in the liver of patients without excess alcohol anamnesis or other reasons for secondary hepatic steatosis. NAFLD is one of the most common reasons of chronic liver disease and is closely associated with obesity and insulin resistance. Recent studies suggest that obesity and obesity comorbidities such as NAFLD, type 2 diabetes, and metabolic syndrome may have connection with low grade chronic inflammation. Clinical studies reveal that prevalence of NAFLD is increasing worldwide. Due to raising prevalence of NAFLD in the recent years, elucidating the pathways of the disease became a major interest in hepatic research. Particularly latest studies indicate that adipose tissue is not only a depot for energy storage but also secrete adipokines or adipocytokines and therefore acts as one of the triggers of NAFLD pathogenesis. The aim of this review is to investigate the effects of adipokines such as leptin tumor necrosis factor (TNF)-α, interleukin (IL)-6, retinol binding protein (RBP)-4 adiponectin, resistin, visfatin, apelin, and chemerin in pathogenesis of NAFLD

PDF

___

1. Stojsavljevic S, Gomercic Palcic M, Virovic Jukic L, Smircic Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014;20(48):18070-18091.
2. Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol 2013;19(6): 802-812.
3. Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 2016;65(8):1017-1025.
4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34(3):274-285.
5. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol 2014;28(4):637-653.
6. Basaranoglu M, Basaranoglu G, Senturk H. From fatty liver to fibrosis: a tale of “second hit”. World J Gastroenterol 2013;19(8):1158-1165.
7. Smith U, Andersson CX, Gustafson B, Hammarstedt A, Isakson P, Wallerstedt E. Adipokines, systemic inflammation and inflamed adipose tissue in obesity and insulin resistance. Int Congr Ser 2007;(1303):31- 34.
8. Tordjman J, Guerre-Millo M, Clement K. Adipose tissue inflammation and liver pathology in human obesity. Diabetes Metab;34(6):658-663.
9. Kalafateli M, Triantos C, Tsochatzis E, Michalaki M, Koutroumpakis E, Thomopoulos K, et al. Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. World J Gastroenterol 2015;21(10):3020-3029.
10. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 2012;18(8):727- 735.
11. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007;56(4):1010-1013.
12. Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016;65(8):1062-1079.
13. Duarte N, Coelho IC, Patarrão RS, Almeida JI, PenhaGonçalves C, Macedo MP. How inflammation impinges on NAFLD: a role for Kupffer cells. Biomed Res Int, 2015;:0-11
14. Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol 2006;44(2):253-261.
15. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132(6):2169-2180.
16. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006;101(11):2629- 2640.
17. Tarantino G, Savastano S, Colao A. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol 2010; 16 (38): 4773-4783.
18. Li Y, Liu L, Wang B, Wang J, Chen D. Simple steatosis is a more relevant source of serum inflammatory markers than omental adipose tissue. Clin Res Hepatol Gastroenterol 2014;38(1):46-54.
19. Genc H, Dogru T, Kara M, Tapan S, Ercin CN, Acikel C, et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol 2013;12 (4):548-555.
20. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF‐α or adiponectin? Hepatology 2004;40(1):46-54.
21. Kukla M, Ciupinska-Kajor M, Kajor M, Wylezol M, Zwirska-Korczala K, Hartleb M, et al. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol J Pathol 2010;61(3):147-153.
22. Aller R, De Luis D, Izaola O, Sagrado MG, Conde R, Velasco M, et al. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci 2009;54(8):1772-1777.
23. Tsutsumi C, Okuno M, Tannous L, Piantedosi R, Allan M, Goodman D, et al. Retinoids and retinoid-binding protein expression in rat adipocytes J Biol Chem 1992;267(3):1805-1810.
24. Chang X, Yan H, Bian H, Xia M, Zhang L, Gao J, et al. Serum retinol binding protein 4 is associated with visceral fat in human with nonalcoholic fatty liver disease without known diabetes: a cross-sectional study. Lipids Health Dis 2015;14(28):1-8.
25. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, et al. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 2007;30(5):1173-1178.
26. Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 2016;59(1):30-43.
27. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010;152(2):93-100.
28. Dalamaga M, Chou SH, Shields K, Papageorgiou P, Polyzos SA, Mantzoros CS. Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab 2013;18(1):29- 42.
29. Frank S, Stallmeyer B, Kämpfer H, Kolb N, Pfeilschifter J. Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. J Clin Invest 2000;106(4):501-509.
30. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004;41(6):943-949.
31. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and metaanalysis. Metabolism 2011;60(3):313-326.
32. Melgar-Lesmes P, Casals G, Pauta M, Ros J, Reichenbach V, Bataller R, et al. Apelin mediates the induction of profibrogenic genes in human hepatic stellate cells. Endocrinology 2010;151(11):5306-5314.
33. Hashım AM, Ali G, Hassan H, El-Sayed A, Amro Ayad M. Serum apelin level and insulin resistance in nonalcoholic fatty liver disease and their relationship to histological severity of liver disease. Med J Cairo Univ 2014;82(1):363-368
34. García-Díaz D, Campión J, Milagro FI, Martínez JA. Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers. Mol Cell Biochem 2007;305(1-2):87-94.
35. Shen C, Zhao CY, Wang W, Wang YD, Sun H, Cao W, et al. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gastroenterol 2014;14(39):1-8
36. Bajaj M, Suraamornkul S, Hardies L, Pratipanawatr T, DeFronzo R. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes (Lond) 2004;28(6):783-789.
37. Jarrar M, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non‐ alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27(5):412-421.
38. Hatziagelaki E, Herder C, Tsiavou A, Teichert T, Chounta A, Nowotny P, et al. Serum chemerin concentrations associate with beta-cell function, but not with insulin resistance in individuals with non-alcoholic fatty liver disease (NAFLD). PloS one 2015;10(5):e0124935.
39. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148(10):4687-4694.
40. Krautbauer S, Wanninger J, Eisinger K, Hader Y, Beck M, Kopp A, et al. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver. Exp Mol Pathol 2013;95(2):199- 205.
41. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rotellar F, Valentí V, et al. Increased levels of chemerin and its receptor, chemokine-like receptor-1, in obesity are related to inflammation: tumor necrosis factor-α stimulates mRNA levels of chemerin in visceral adipocytes from obese patients. Surg Obes Relat Dis 2013;9(2):306-314.
42. Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2010;95(6):2892-2896.
43. Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol Suppl 2010;45(2):235-242.
44. Jamali R, Razavizade M, Arj A, Aarabi MH. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease. World J Gastroenterol 2016;22(21): 5096-5103
45. Polyzos S, Kountouras J, Zavos C. The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease. Hippokratia 2009;13(2):127
46. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterol 2006;131(3):934-945.
47. Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-κB: effects on liver homeostasis and beyond. Endocr Rev 2007;28(4):365-386.
48. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005;54(10):2939-2945.
49. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003;278(46):45777-45784.
50. Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, et al. Serum adipokine levels predictive of liver injury in non‐alcoholic fatty liver disease. Liver Int 2009;29(9):1431-1438.